Alzheimer’s Disease: Continued Clinical Failure and a Potential New Development Pathway

Alzheimer’s disease continues to be a costly and frustrating minefield for drug developers. Most recently, Boehringer Ingelheim halted development of the phosphodiesterase type 9 (PDE9) inhibitor BI 409306 after it failed in phase 2. Merck also ended its trial of verubecestat,… Read »

Setting (Financial) Records in I/O

 On February 14, Bristol-Myers Squibb (BMS) and Nektar announced the largest-ever deal in history involving a single development-stage drug in a partnership that greatly expands combination testing of BMS’s checkpoint inhibitor Opdivo (nivolumab) and Nektar’s T-cell stimulating molecule NKTR-214.  … Read »

Merger Mania

Back in January, one of our predictions for the year included a ramp up in M&A activities on all fronts, driven in part by corporate tax reductions that left many companies with plenty of cash for acquisitions. While news during… Read »

Reinventing Medical Affairs to the Benefit of All

The concept of patient-centric drug development has been a frequent topic of discussion in recent years. Increasingly, companies have moved to adopt practices that create more active, networked relationships and interactions between physicians, patients, advocates and drug developers. The aim… Read »

Enter the Giants: Amazon, Berkshire Hathaway and J.P. Morgan Take on Healthcare

Recent months have seen a series of corporate actions aimed at reconfiguring healthcare in the United States, beginning with drug store giant CVS’s bid in December 2017 to purchase Aetna, one of the country’s biggest insurers, for about $69 billion…. Read »

Lynparza — Extending Cancer Treatment Based on Underlying Genetic Cause

On January 12, the U.S. Food and Drug Administration approved Lynparza (olaparib), the PARP inhibitor partnered by AstraZeneca and Merck, for the treatment of BRCA-mutated, HER2-negative advanced metastatic breast cancer.   The FDA’s action adds another cancer type for Lynparza;… Read »

New Large-Scale Genomic/Health Data Effort Launched, with More to Come

A recently announced six-member consortium of pharmaceutical companies is planning to turn the UK Biobank into the world’s largest publicly accessible concentration of genetic and health data. The effort is being led by Regeneron, which will perform the work at… Read »

Alzheimer’s Disease: The Case for Drug-Diagnostic Partnerships

Developing an Alzheimer’s disease drug has been notoriously expensive and high risk. Part of the problem has been the difficulty in identifying the right patients for clinical trials and at the right time – that is, those patients showing early… Read »

Celebrating Clinical Success in Depression

Depression is a difficult problem for drug developers. Current marketed antidepressants are effective for a relatively small percentage of patients (about 20 in 100) and most require weeks of treatment to show an effect. Patients often need to try several… Read »

Welcome to 2018! What we are watching for JPM18 and the coming year…

Now that the holidays have wound down, we look forward to catching up with many of you in person as the Bionest team and many others from across the healthcare business world descend on San Francisco next week for the… Read »

1 2 3 9